Evidence map›Paper›PMID 37175674›Full record

ArticleInternational journal of molecular sciences2023

In Vivo Efficacy and Toxicity of an Antimicrobial Peptide in a Model of Endotoxin-Induced Pulmonary Inflammation.

Laura Cresti, Giovanni Cappello, Silvia Vailati, Elsa Melloni, Jlenia Brunetti, Chiara Falciani, Luisa Bracci, Alessandro Pini

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. SET-M33 peptide as a selectiveMicrobiology spectrum · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Laura CrestiU.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy.
Giovanni CappelloMedical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy.
Silvia VailatiZambon spa, Via A. Meucci 3, 20091 Bresso, Italy.
Elsa MelloniZambon spa, Via A. Meucci 3, 20091 Bresso, Italy.
Jlenia BrunettiMedical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy.ORCID 0000-0001-8144-7186
Chiara FalcianiMedical Biotechnology Department, University of Siena, Via A Moro 2, 53100 Siena, Italy.ORCID 0000-0002-1027-8482
Luisa BracciU.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy.ORCID 0000-0002-0738-5746
Alessandro PiniU.O.C. Clinical Pathology, Azienda Ospedaliera Universitaria Senese, Via M. Bracci, 53100 Siena, Italy.
University of Siena · ITZambon (Italy) · IT

Funding

HORIZON-MSCA-2021-DN-01 101073263Italian NRRP, Tuscany Health Ecosystem SPOKE 7 D.D. n. 1050 23/06/2022Regione Toscana, Italy, CALL COVID-19 DD 19049 17/11/2020
6 · The paper itself

Abstract

SET-M33 is a synthetic peptide that is being developed as a new antibiotic against major Gram-negative bacteria. Here we report two in vivo studies to assess the toxicity and efficacy of the peptide in a murine model of pulmonary inflammation. First, we present the toxicity study in which SET-M33 was administered to CD-1 mice by snout inhalation exposure for 1 h/day for 7 days at doses of 5 and 20 mg/kg/day. The results showed adverse clinical signs and effects on body weight at the higher dose, as well as some treatment-related histopathology findings (lungs and bronchi, nose/turbinates, larynx and tracheal bifurcation). On this basis, the no observable adverse effect level (NOAEL) was considered to be 5 mg/kg/day. We then report an efficacy study of the peptide in an endotoxin (LPS)-induced pulmonary inflammation model. Intratracheal administration of SET-M33 at 0.5, 2 and 5 mg/kg significantly inhibited BAL neutrophil cell counts after an LPS challenge. A significant reduction in pro-inflammatory cytokines, KC, MIP-1α, IP-10, MCP-1 and TNF-α was also recorded after SET-M33 administration.

Indexed as

EndotoxinsPneumoniaAnimalsAntimicrobial PeptidesBronchoalveolar Lavage FluidCytokinesInflammationLipopolysaccharidesMicePeptidesAntimicrobial PeptidesCytokinesEndotoxinsLipopolysaccharidesPeptidesanti-inflammatory efficacyantimicrobial peptidein vivo toxicityNOAELpulmonary inflammation

Identifiers

PMID37175674
PMCPMC10178222
OpenAlexW4367320125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.